The Mitsubishi Life Science Institute has launched a clinical trial with MUSE cells (multi-lineage differentiating stress enduring cells) for the treatment of acute myocardial infarction in January, 2018. Now, LSI annunces a clinical trial CL2020 with MUSE cells targeting patients with cerebral infarction. In this trial, MUSE cells will be administered intravenously.

LSI news release, September 3, 2018